[go: up one dir, main page]

WO2008121160A3 - Anticorps optimisés qui ciblent cd5 - Google Patents

Anticorps optimisés qui ciblent cd5 Download PDF

Info

Publication number
WO2008121160A3
WO2008121160A3 PCT/US2007/083247 US2007083247W WO2008121160A3 WO 2008121160 A3 WO2008121160 A3 WO 2008121160A3 US 2007083247 W US2007083247 W US 2007083247W WO 2008121160 A3 WO2008121160 A3 WO 2008121160A3
Authority
WO
WIPO (PCT)
Prior art keywords
target
antibodies
optimized antibodies
parent antibody
alters
Prior art date
Application number
PCT/US2007/083247
Other languages
English (en)
Other versions
WO2008121160A2 (fr
Inventor
Matthew J Bernett
John R Desjarlais
Sher Bahadur Karki
Eugene Alexander Zhukovsky
Erik Weiking Pong
Seung Yup Chu
Original Assignee
Xencor Inc
Matthew J Bernett
John R Desjarlais
Sher Bahadur Karki
Eugene Alexander Zhukovsky
Erik Weiking Pong
Seung Yup Chu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc, Matthew J Bernett, John R Desjarlais, Sher Bahadur Karki, Eugene Alexander Zhukovsky, Erik Weiking Pong, Seung Yup Chu filed Critical Xencor Inc
Publication of WO2008121160A2 publication Critical patent/WO2008121160A2/fr
Publication of WO2008121160A3 publication Critical patent/WO2008121160A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps qui ciblent CD19, les anticorps comprenant au moins une modification par rapport à un anticorps parent, la modification changeant l'affinité pour un FcgR ou changeant une fonction effectrice par comparaison avec l'anticorps parent. L'invention concerne également des procédés d'utilisation des anticorps.
PCT/US2007/083247 2006-11-21 2007-10-31 Anticorps optimisés qui ciblent cd5 WO2008121160A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86679306P 2006-11-21 2006-11-21
US60/866,793 2006-11-21

Publications (2)

Publication Number Publication Date
WO2008121160A2 WO2008121160A2 (fr) 2008-10-09
WO2008121160A3 true WO2008121160A3 (fr) 2009-01-22

Family

ID=39808822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083247 WO2008121160A2 (fr) 2006-11-21 2007-10-31 Anticorps optimisés qui ciblent cd5

Country Status (1)

Country Link
WO (1) WO2008121160A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
UA121453C2 (uk) 2008-04-11 2020-06-10 Чугей Сейяку Кабусікі Кайся Спосіб одержання фармацевтичної композиції, яка містить антитіло
US8455249B2 (en) 2009-05-01 2013-06-04 The University Of Tokyo Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
WO2011089211A1 (fr) * 2010-01-22 2011-07-28 Synimmune Gmbh Anticorps anti-cd133 et leurs procédés d'utilisation
US9187552B2 (en) 2010-05-27 2015-11-17 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
BR112015024587B1 (pt) 2013-04-02 2022-11-29 Chugai Seiyaku Kabushiki Kaisha Variante de região fc de igg1 humana, polipeptídeo compreendendo a mesma, seu método de produção e composição farmacêutica
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EP3816179A3 (fr) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Variant de région fc comprenant un domaine de liaison fcrn modifié
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR102102734B1 (ko) 2016-08-05 2020-04-22 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019108863A1 (fr) * 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions et procédés pour la déplétion des cellules cd5+
JP7508368B2 (ja) 2018-03-15 2024-07-01 中外製薬株式会社 ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法
ES2973518T3 (es) 2018-06-03 2024-06-20 Lamkap Bio Beta Ag Anticuerpos biespecíficos contra CEACAM5 y CD47
CN112739340B (zh) * 2018-07-23 2025-05-13 海德堡医药研究有限责任公司 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
EP3831849A1 (fr) 2019-12-02 2021-06-09 LamKap Bio beta AG Anticorps bispécifiques contre ceacam5 et cd47
EP3915641A1 (fr) * 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anticorps anti-cd5 et leurs procédés d'utilisation
US20230340141A1 (en) * 2020-08-21 2023-10-26 City Of Hope Anti-cd5 antibody compositions and uses thereof
US20240041932A1 (en) 2020-09-14 2024-02-08 Vor Biopharma Inc. Compositions and methods for cd5 modification
WO2022127844A1 (fr) * 2020-12-17 2022-06-23 江苏先声药业有限公司 Anticorps cd5 et son utilisation
PL4055055T3 (pl) 2020-12-18 2024-04-15 Lamkap Bio Beta Ag Przeciwciała dwuswoiste przeciwko ceacam5 i cd47
CN116829600A (zh) * 2021-01-12 2023-09-29 南京驯鹿生物技术股份有限公司 靶向cd5的全人源抗体
CN113105547B (zh) * 2021-05-18 2022-04-08 福州迈新生物技术开发有限公司 抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用
US12077597B2 (en) 2021-11-24 2024-09-03 International-Drug-Development-Biotech Anti-CD5 antibodies and methods of use thereof
CN119998319A (zh) 2022-06-16 2025-05-13 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
WO2025179294A2 (fr) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Amplification d'ingénierie immunitaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008883A1 (en) * 2003-12-04 2006-01-12 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (fr) * 2005-03-31 2006-10-05 Xencor, Inc. Variants fc presentant des proprietes optimisees

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008883A1 (en) * 2003-12-04 2006-01-12 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (fr) * 2005-03-31 2006-10-05 Xencor, Inc. Variants fc presentant des proprietes optimisees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTIN J H ET AL: "Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.", BLOOD 15 OCT 1991, vol. 78, no. 8, 15 October 1991 (1991-10-15), pages 2139 - 2149, XP002505318, ISSN: 0006-4971 *
CIOCA D P ET AL: "Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K MAR 2002, vol. 16, no. 3, March 2002 (2002-03-01), pages 335 - 343, XP002505317, ISSN: 0887-6924 *
PERS J O ET AL: "CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K JAN 2002, vol. 16, no. 1, January 2002 (2002-01-01), pages 44 - 52, XP002505316, ISSN: 0887-6924 *
STUDNICKA G M ET AL: "HUMAN-ENGINEERED MONOCLONAL ANTIBODIES RETAIN FULL SPECIFIC BINDINGACTIVITY BY PRESERVING NON-CDR COMPLEMENTARITY-MODULATING RESIDUES", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 7, no. 6, 1 June 1994 (1994-06-01), pages 805 - 814, XP000447301, ISSN: 0269-2139 *

Also Published As

Publication number Publication date
WO2008121160A2 (fr) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2008121160A3 (fr) Anticorps optimisés qui ciblent cd5
WO2008022152A3 (fr) Anticorps optimisés ciblant cd19
WO2008091798A3 (fr) Anticorps de ca9 optimises et methodes d'utilisation associees
WO2008091954A3 (fr) Anticorps cd40 optimisés et leurs procédés d'utilisation
WO2008098115A3 (fr) Anti-corps igf-1r optimisés et procédés utilisant ceux-ci
WO2007044616A3 (fr) Anticorps anti-cd30 optimises
WO2009026117A3 (fr) Nouveaux composés
WO2007024846A3 (fr) Anticorps anti-il-23
WO2008036688A3 (fr) Anticorps optimisés ciblant l'antigène hm1.24
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
WO2008048519A3 (fr) Anticorps se liant aux épitopes de cxcr7
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
WO2005092925A3 (fr) Variantes d'immunoglobuline a l'exterieur de la region fc
WO2004072266A3 (fr) Ingenierie de l'affinite des anticorps par un remplacement complementaire en serie guide par epitope
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2006130374A3 (fr) Anticorps se liant a tweak
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2008060705A3 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2007008583A3 (fr) Resultats et application ameliores d'epreuves de comparaison d'expressions proteiniques
WO2009081285A3 (fr) Anticorps contre le virus de l'hépatite c
WO2006135527A3 (fr) Procedes de selection d'aptameres
WO2008140570A3 (fr) Anticorps à sélectivité de protéine a
WO2007127506A3 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
WO2008030564A3 (fr) Anticorps aglycosylés et procédés de fabrication et d'utilisation de ces anticorps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873582

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07873582

Country of ref document: EP

Kind code of ref document: A2